Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
B-cell lymphoma
Biotech
Has Novartis’ T-Charge push been overtaken by in vivo CAR-Ts?
It’s been over four years since Novartis shook up the CAR-T space with its T-Charge platform. But that’s a lifetime in the world of cell therapies.
James Waldron
May 22, 2026 8:28am
Allogene’s off-the-shelf CAR-T erases lingering lymphoma cells
Apr 13, 2026 7:45am
J&J lymphoma CAR-T hits 100% ORR in 10 patients
Jun 13, 2025 1:22pm
Radiance joins ROR1 race, paying $15M for ADC to challenge Merck
Feb 19, 2025 7:32am
Allogene’s lymphoma data show CAR-T could ‘leapfrog’ competition
Feb 14, 2025 10:35am
Astellas stops development of early-stage lymphoma CAR-T
Jan 9, 2025 6:49am
